Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 19-20/2015

01.10.2015 | original article

EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice

verfasst von: Margit Hemetsberger, Rainer Oberbauer, Helmut Erb, OA Dr. Wolfgang Pronai

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 19-20/2015

Einloggen, um Zugang zu erhalten

Summary

The EARLIER (Evaluation of MimpARa in incident hemodiaLysis patIEnts with secondaRy hyperparathyroidism; SHPT) observational postmarketing surveillance study evaluated incident hemodialysis patients (< 1 year dialysis vintage; n = 146) receiving cinacalcet in Austrian clinical practice. Despite intervention with vitamin D sterols and phosphate binders, 24 % had already developed severe SHPT (intact parathyroid hormone (iPTH) > 800 pg/mL) at baseline. After cinacalcet was started, median iPTH decreased substantially, from 611 pg/mL to 251 pg/mL (median decrease 58 % [IQR − 36 to − 78 %] at 12 months. Overall, 36 % of patients achieved the Kidney Disease Outcomes Quality Initiative (K/DOQI) target range (150–300 pg/mL) for iPTH; this included 35 % of those with severe SHPT at baseline. Serum phosphorus (P), calcium (Ca) (corr), and Ca (corr) × P also decreased, with 43, 34, and 62 % of patients, respectively, reaching K/DOQI targets at 12 months. Thus, in this observational study, mineral metabolism in incident dialysis patients with SHPT improved after starting cinacalcet.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Billa V, Zhong A, Bargman J, Vas S, Wong PY, Oreopoulos DG. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit Dial Int. 2000;20(3):315–21.PubMed Billa V, Zhong A, Bargman J, Vas S, Wong PY, Oreopoulos DG. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit Dial Int. 2000;20(3):315–21.PubMed
2.
Zurück zum Zitat Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis. 1997;29(6):862–5.CrossRefPubMed Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis. 1997;29(6):862–5.CrossRefPubMed
3.
Zurück zum Zitat Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:S14–9.CrossRefPubMed Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:S14–9.CrossRefPubMed
4.
Zurück zum Zitat Tominaga Y, Takagi H. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens. 1996;5(4):336–41.CrossRefPubMed Tominaga Y, Takagi H. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens. 1996;5(4):336–41.CrossRefPubMed
5.
Zurück zum Zitat Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant. 2007;22(7):1828–39.CrossRefPubMed Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant. 2007;22(7):1828–39.CrossRefPubMed
6.
Zurück zum Zitat Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.CrossRefPubMed Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.CrossRefPubMed
7.
Zurück zum Zitat Kestenbaum B, Belozeroff V. Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest. 2007;37(8):607–22.CrossRefPubMed Kestenbaum B, Belozeroff V. Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest. 2007;37(8):607–22.CrossRefPubMed
8.
Zurück zum Zitat Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2004;43(3):572–9.CrossRefPubMed Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis. 2004;43(3):572–9.CrossRefPubMed
9.
Zurück zum Zitat Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.CrossRefPubMed Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.CrossRefPubMed
10.
Zurück zum Zitat Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25.CrossRefPubMed Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25.CrossRefPubMed
11.
Zurück zum Zitat Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800–7.CrossRefPubMed Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800–7.CrossRefPubMed
12.
Zurück zum Zitat Zitt E, Jager C, Rosenkranz AR, Eigner M, Kodras K, Kovarik J, et al. Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients–results of the Austrian cohort of the ECHO study. Wien Klin Wochenschr. 2011;123(1–2):45–52.CrossRefPubMed Zitt E, Jager C, Rosenkranz AR, Eigner M, Kodras K, Kovarik J, et al. Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients–results of the Austrian cohort of the ECHO study. Wien Klin Wochenschr. 2011;123(1–2):45–52.CrossRefPubMed
13.
Zurück zum Zitat Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3(1):36–45.PubMedCentralCrossRefPubMed Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3(1):36–45.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Moe SM, Smirnakis KV, Ling X, Turner SA, Bushinsky DA, editors Early initiation of cinacalcet HCl for the treatment of secondary hyperparathyroidism (SHPT) improves KDOQITM goal attainment. Annual Meeting of the American Society of Nephrology; 2006; San Diego. Moe SM, Smirnakis KV, Ling X, Turner SA, Bushinsky DA, editors Early initiation of cinacalcet HCl for the treatment of secondary hyperparathyroidism (SHPT) improves KDOQITM goal attainment. Annual Meeting of the American Society of Nephrology; 2006; San Diego.
15.
Zurück zum Zitat Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2009;24(3):982–9.PubMedCentralCrossRefPubMed Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2009;24(3):982–9.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Terawaki H, Nakano H, Takeguchi F, Hasegawa T, Nakayama M, Okazaki M, et al. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant. 2009;24(2):690-1. (author reply 1–2). Terawaki H, Nakano H, Takeguchi F, Hasegawa T, Nakayama M, Okazaki M, et al. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant. 2009;24(2):690-1. (author reply 1–2).
17.
Zurück zum Zitat Komaba H, Fukagawa M. Regression of parathyroid hyperplasia by calcimimetics–fact or illusion? Nephrol Dial Transplant. 2009;24(3):707–9.CrossRefPubMed Komaba H, Fukagawa M. Regression of parathyroid hyperplasia by calcimimetics–fact or illusion? Nephrol Dial Transplant. 2009;24(3):707–9.CrossRefPubMed
18.
Zurück zum Zitat Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5(12):2305–14.PubMedCentralCrossRefPubMed Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5(12):2305–14.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53(2):197–207.CrossRefPubMed Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53(2):197–207.CrossRefPubMed
20.
Zurück zum Zitat National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):1–201. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):1–201.
21.
Zurück zum Zitat KDIGO. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76(113):S1–130. KDIGO. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76(113):S1–130.
22.
Zurück zum Zitat Block GA. The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease. Kidney international. 2003;64(87):S131–6. Block GA. The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease. Kidney international. 2003;64(87):S131–6.
Metadaten
Titel
EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice
verfasst von
Margit Hemetsberger
Rainer Oberbauer
Helmut Erb
OA Dr. Wolfgang Pronai
Publikationsdatum
01.10.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 19-20/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-015-0379-0

Weitere Artikel der Ausgabe 19-20/2015

Wiener Medizinische Wochenschrift 19-20/2015 Zur Ausgabe